PharmGen Science, Inc. (004720.KS) Financial Forecast
South Korea · Healthcare · KRW (Millions) · Annual
Key financials
KRW|Millions
ROE
-58.95%
2025 (actual)
ROA
-41.74%
2025 (actual)
Gross Margin
64.53%
2025 (actual)
Net Margin
-67.39%
2025 (actual)
Total Assets
₩195,413.59M
2025 (actual)
Net Income
-₩116,641.03M
2025 (actual)
Valuation
₩91,046.82M
2026 (forecast)
Stock Price
₩4,155
Historical & projected performance
KRW|Millions
Reported figures and Equlion model projections for the next 5 years.
ROE
+96.2 pt
Company
ROA
-72 pt
Company
Gross Margin
-9.3 pt
Company
Sector average
Net Margin
-34.1 pt
Company
Total Assets
+37%
Company
Sector average
Net Income
-152.9%
Company
Sector average (own scale)
Valuation
+111.9%
Company
Sector average (own scale)
Stock Price
+111.9%
Company
Sector average (own scale)
Amounts in KRW (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.
Want the full financial forecast report for PharmGen Science, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.